×
Behold: Horror Icons Are Getting the Baby Yoda Treatment

Behold: Horror Icons Are Getting the Baby Yoda Treatment

It seems these days most major franchises want to cash in on that Star Wars Baby Yoda money by making their own adorable version of something within any given fandom. We saw it last year with the debut of Baby Beetlejuice in Beetlejuice Beetlejuice, and now this year we have Spirit Halloween‘s Horror Babies.

The cuteness aggression is too real with Terrifier star Art the Clown—plus Chucky, Ghostface, lil’ Michael Myers, Leatherface, Pennywise, and others, all featured as infants in the Spirit Halloween line. You just want to hold them and let them love you to death, ya know? We particularly love Pink Ghostface and the sunglass-wearing Art, who delight with bold, bright colors and playful poses.

Take a look at the lineupbelow!

 

According to Spirit Halloween, the dolls range in price from $15 for the mini to $55 for the full-size. The smaller options appear to be in stores and have dimensions of 4″ H x 2.8″ W x 4″ D.

Meanwhile, the ones that approximate the size of actual human babies are made of foam filled with latex and are 12.5″ H x 12.5″ W x 8.8″ D. Some of the bigger ones will be available at the seasonal Halloween pop-up but others, like Leatherface and Pink Ghostface, appear to be online only. These are so good and, honestly, a good chilling chibi take on iconic horror titans that fans will definitely add to their collections. Happy Halloween hunting!

Find them online at Spirit Halloween or in stores.

Want more io9 news? Check out when to expect the latest Marvel, Star Wars, and Star Trek releases, what’s next for the DC Universe on film and TV, and everything you need to know about the future of Doctor Who.

Source link
#Behold #Horror #Icons #Baby #Yoda #Treatment

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damageSamsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech

Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech">Samsung’s new foldable display is harder to crease and damage

Samsung has unveiled a new flexible display technology for foldable phones that’s designed to be slimmer, more durable, and less prone to creasing. The Flex Titanium tech is the culmination of everything that the company has learned over seven generations of foldables, according to Samsung, and will debut with the upcoming Galaxy Z Fold 8 and Galaxy Z Fold 8 Ultra. And since Samsung Display is a long-time Apple supplier, this improved display might even appear in the rumored iPhone foldable expected later this year.

As its name suggests, the Flex Titanium display uses a combination of two titanium-based components to improve strength, flexibility, and slimness. A titanium-alloy film provides structural support from underneath the OLED panel, providing “20 times greater mechanical stiffness” compared to polymer film, and measures about one-third the thickness of an average human hair.

A titanium plate located under the film enables tighter bonding with the display module, improving stability when unfolded while “retaining the flexibility needed to accommodate repeated folding,” according to Samsung. This new display tech will also consume less power and produce “ultra-vivid” display visual resolution.

“Together, these advancements enable a strong foldable display that maximizes content immersion on a seamless screen and reduces crease visibility — all while keeping it slim,” Samsung said in its announcement. “By balancing strength, flexibility and structural stability, Samsung continues to set the bar for foldable displays.”

Further details about the display will be available at Samsung’s Galaxy Unpacked event on July 22nd where Samsung’s latest foldables are expected to be showcased.

#Samsungs #foldable #display #harder #crease #damageFoldable Phones,Mobile,News,Samsung,Tech
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at B | TechCrunch
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about 0 million at a  billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.







Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised 0 million at a .8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a .1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI">OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B | TechCrunch

Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge of his plans. Several other OpenAI researchers are expected to join the new company.  

Wang is in talks to raise about $200 million at a $2 billion valuation, two of the people said. Lightspeed is in discussions to lead the funding round, according to sources. Talks are ongoing, the deal may not be final and details could change.

Wang disputed the story’s funding figures and description of the company but did not specify the correct numbers or details. Lightspeed didn’t respond to a request for comment.

The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences. Chai Discovery, a two-year-old startup developing AI models that can predict molecular interactions to identify new drugs, announced on Tuesday that it raised $400 million at a $3.8 billion valuation. (Co-founder Josh Meier also passed through OpenAI as a researcher.) Meanwhile, Google DeepMind spinout Isomorphic Labs, which also develops AI models for drug discovery, raised a $2.1 billion Series B in May.

Wang’s new startup may be working on AI models that will help find new uses for existing drugs and possibly those that previously failed in trials, a couple of sources told TechCrunch. Finding new uses for FDA-approved drugs can result in significantly faster time to revenue than developing new drugs from scratch, as these medicines have already been tested for safety.

Wang joined OpenAI in 2024 after dropping out from Harvard, where he was working on a bachelor’s degree in computer science. (In recent years, investors are once again comfortable betting on young founders who haven’t completed college.)

At OpenAI, he co-authored research papers, including evaluating how AI models can automate and accelerate scientific discovery.

When you purchase through links in our articles, we may earn a small commission. This doesn’t affect our editorial independence.

#OpenAI #researcher #Miles #Wang #talks #launch #drug #discovery #startup #valued #TechCrunchdrug discovery,lightspeed,OpenAI

Post Comment